ArticleBMC cancer2022

Dual targeting of FGFR3 and ERBB3 enhances the efficacy of FGFR inhibitors in FGFR3 fusion-driven bladder cancer.

Andrew J Weickhardt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.